Literature DB >> 3573540

The effects of intraperitoneal calcitriol on calcium and parathyroid hormone.

J A Delmez, C S Dougan, B K Gearing, M Rothstein, D W Windus, N Rapp, E Slatopolsky.   

Abstract

Parathyroid suppression by intraperitoneal calcitriol (1,25(OH)2D3) during peritoneal dialysis. The purpose of this study was to determine if parathyroid hormone (PTH) suppression could be achieved by increasing calcium mass transfer (Ca MT) with high dialysate Ca (4 mEq/liter) or via intraperitoneal (i.p.) 1,25(OH)2D3 in patients undergoing continuous ambulatory peritoneal dialysis. Eleven patients were dialyzed for two months with standard Ca dialysate (3.5 mEq/liter) followed by two months with 4.0 mEq/liter Ca, then by three months of i.p. 1,25(OH)2D3. During the latter period, patients were randomized to groups whose dialysate contained either 3.5 mEq/liter or 4.0 mEq/liter Ca. We found that 4.0 mEq/liter Ca dialysate more than doubled Ca MT (37 +/- 17 mg/day to 84 +/- 6 mg/day) leading to a modest fall (P less than 0.05) in PTH levels (84 +/- 5.5% of controls). Ionized calcium levels did not change. With i.p. 1,25(OH)2D3, however, ionized calcium rose significantly (P less than 0.001) leading to a decline in PTH levels to 53.9 +/- 7.9% of control values. Serum 1,25(OH)2D3 levels rose from undetectable to 47.7 +/- 7.2 pg/dl (normal range 20 to 35). These studies indicate that increasing Ca MT using a 4.0 mEq/liter Ca dialysate leads to a small reduction in PTH concentrations. On the other hand, i.p. 1,25(OH)2D3 is well absorbed into the systemic circulation, raises ionized calcium levels, and leads to a marked suppression of PTH. Thus, i.p. 1,25(OH)2D3 may be a simple and effective means to suppress secondary hyperparathyroidism in patients undergoing CAPD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3573540     DOI: 10.1038/ki.1987.68

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  Chronotherapy of high-dose active Vitamin D(3): is evening dosing preferable?

Authors:  Cheryl P Sanchez
Journal:  Pediatr Nephrol       Date:  2004-07       Impact factor: 3.714

2.  The management of renal osteodystrophy.

Authors:  I B Salusky; W G Goodman
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

Review 3.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

4.  Intraperitoneal Calcitriol for Treatment of Severe Hyperparathyroidism in Children with Chronic Kidney Disease: A Therapy Forgotten.

Authors:  Rahul Chanchlani; Susan Ackerman; Elizabeth Piva; Elizabeth Harvey
Journal:  Perit Dial Int       Date:  2016 11-12       Impact factor: 1.756

5.  Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.

Authors:  J A Delmez; C Tindira; P Grooms; A Dusso; D W Windus; E Slatopolsky
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 6.  Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review.

Authors:  Roberto Russo; Marinella Ruospo; Mario Cozzolino; Luca De Nicola; Andrea Icardi; Ernesto Paoletti; Sandro Mazzaferro
Journal:  J Nephrol       Date:  2014-07-11       Impact factor: 3.902

Review 7.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.